Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laromustine and Hydroxyurea in AML or High-Risk MDS
NCT00083187Phase 2Completed
- Sponsor
- Vion Pharmaceuticals
- Start
- Nov 2005
- Primary completion
- Jan 2007
- Countries
- 3
01
Overview
A Phase 2 trial of laromustine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Vion Pharmaceuticals. Started Nov 2005; status: completed.
02
Drugs
laromustine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00083187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083187.